Clinical Trial Update: Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C) [Phase 2]

View source ↗

Summary

Phase 2 MATCH subprotocol Z1C evaluates palbociclib in cancers with CDK4/CDK6 amplification; results have been posted and the trial is currently active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-12-10